Korea sends world-class products into Germany — biosimilars, medtech, digital health, mobility — and enters with two real advantages few origins have. But Germany's operating logic, and its reimbursement system, still work in ways Korean teams need to plan for. Here's the map.
For a Korean company, Germany is the natural EU base — and Korea enters with two advantages: an EU adequacy decision (personal data flows from the EU to Korea without extra safeguards) and the EU–Korea Free Trade Agreement. But the operating model still differs: a GmbH with an accountable managing director, strong employment protection, German business formality, and — for life sciences — a reimbursement system where a marketing authorization or CE mark only lets you sell. What you're actually paid is assessed and negotiated.
Korean companies rarely lack a competitive product — in biosimilars, diagnostics, devices and digital health, many are global leaders. The gap is the market's operating logic, not the offering.
German business rewards planning, formality and long relationships over speed, and its healthcare system decouples “allowed to sell” from “paid.” Korea's advantages open the door faster than most origins; the work is turning that head start into reimbursed revenue and durable local relationships.
Korea's product wins on merit. Germany still makes you win on structure and access.
Two structural features give Korean entrants a head start most origins — notably the US — don't have.
Since Dec 2021, personal data flows from the EU to Korea without extra safeguards — no SCCs or transfer-impact assessment, unlike US transfers. (Subject to periodic EU review.)
The free-trade agreement (in force since 2011) removes most tariffs and eases market access for Korean goods into the EU.
Korea is a global force in biosimilars, biologics CDMO, diagnostics and connected devices — credible from the first meeting.
These are real advantages — but they get you to the German market, not through its reimbursement and procurement gates. That's the part to plan.
The areas that feel settled at home behave differently here. This is the shortlist most Korean entrants wish they'd mapped first.
Most Korean companies operate through a German GmbH — a limited company with €25,000 minimum capital, notarised formation, and a managing director (Geschaeftsfuehrer) who carries personal duties. Sending staff without an entity risks creating a permanent establishment and an unplanned tax presence — the structure decision should come first (see structuring an investment in Germany).
Two cultural shifts matter most:
Korea's strength in biosimilars, biologics, diagnostics and digital health is exactly where the German gap bites hardest. A marketing authorization or CE mark lets you sell — but what you're actually paid runs through a separate system, and each track has its own mechanism:
Biosimilars in particular compete through rebate contracts, hospital tenders and regional prescribing quotas — a commercial game, not just an approval. The reimbursement and access case belongs in the plan from day one, which is the layer we own.
Korean entrants don't start from zero. Real on-the-ground help exists:
These open doors and networks; converting them into reimbursed revenue and the right distribution partners is where a market-access boutique earns its place.
In a focused session we map the entity and tax setup, the reimbursement route that decides your revenue, and the right distribution and hospital partners — so your advantages translate into paid, durable market presence. Germany first; the EU from there.